1-2 of 2
Marcus Lefebure, PhD BSc
Close
Sort by
Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Barbara F. Eichhorst, MD, Peter Hillmen, MD PhD, James D'Rozario, MBBS, FRACP, FRCPA, Sarit Assouline, MD, Carolyn Owen, MD, Tadeusz Robak, MD, Javier de la Serna, MD PhD, Ulrich Jaeger, MD, Guillaume Cartron, Marco Montillo, MD, Nicole Lamanna, MD, Su Young Kim, MD PhD, Jenny Wu, MS, Yanwen Jiang, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Arnon P Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 355.
https://doi.org/10.1182/blood-2019-123930
Published: 2019
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019